The Bacillus Calmette-Guérin (BCG) vaccine, a tuberculosis treatment, may offer a new path for Alzheimer’s disease prevention by retraining the innate immune system. A pilot study published in Communications Medicine found that BCG vaccination altered immune cell behavior and biomarkers in the cerebrospinal fluid of older adults, according to Steven Arnold, MD, of Massachusetts General Hospital.
How does the BCG vaccine affect Alzheimer’s biomarkers?
In a year-long, open-label trial, researchers observed that BCG vaccination induced “trained immunity”—a long-lasting reprogramming of the innate immune system. According to Dr. Arnold, participants without existing Alzheimer’s pathology showed a notable shift: decreased amyloid-beta levels in their cerebrospinal fluid and a corresponding increase in blood amyloid levels. This suggests the vaccine may influence how the central nervous system clears proteins linked to cognitive decline. However, this shift was not observed in participants who already exhibited Alzheimer’s-related pathology, indicating that the timing of the intervention may be critical to its effectiveness.
What is the current status of BCG research for dementia?
While the study demonstrates biological changes, it was not designed to prove that the vaccine prevents or treats Alzheimer’s disease. Dr. Arnold emphasized that the research was a small-scale pilot focused on safety and biological mechanisms. Participants in the study included 12 individuals without Alzheimer’s pathology and 11 individuals with Alzheimer’s pathology and mild cognitive impairment or mild-to-moderate Alzheimer’s. Only one case of injection site dermatitis was reported, with no other adverse events attributed to the vaccine.
Pierre Tariot, MD, of the Banner Alzheimer’s Institute, who was not involved in the study, noted that the findings suggest a “durable, disease-modifying modulation of the aging neuroimmune environment.” This research aligns with a growing body of evidence suggesting that vaccines for influenza, pneumonia, and shingles may also be associated with a reduced risk of Alzheimer’s.
What are the next steps for clinical trials?
The research team is now moving toward a large, randomized controlled trial to determine if BCG can effectively reduce the risk of cognitive decline. If funded, the trial would test BCG within a "real-world prevention framework," monitoring cognitive trajectories and Alzheimer’s biomarkers in a larger population of older adults.
Frequently Asked Questions
Has the BCG vaccine been proven to cure Alzheimer’s?
No. According to Dr. Arnold, this study was a small, open-label pilot designed to test safety and biological mechanisms, not to prove the vaccine prevents or treats the disease.
Why is the timing of the vaccine considered important?
The study found that immune changes and protein clearance shifts occurred in participants without Alzheimer’s pathology, but not in those who already had the disease. This suggests that the vaccine may be more effective as an early prevention strategy.
Is this the same vaccine used in childhood?
The study specifically tested a vaccination strategy in older adults (ages 55 and older). It did not examine the effects of childhood BCG vaccination, which is common in many parts of the world, including sub-Saharan Africa, Southeast Asia and parts of Eastern Europe.
Are you interested in the intersection of immunology and brain health? Subscribe to our research newsletter for updates on upcoming clinical trials and the latest developments in neurodegenerative disease prevention.
